A method with safety and convenience to synthesize Regorafenib
DOI:
https://doi.org/10.54097/hset.v40i.6670Keywords:
Regorafenib, nucleophilic, substitution, electronegative, recrystallize.Abstract
To date, three methods have been developed to synthesize Regorafenib, a drug which can effectively cure colorectal cancer. However, all of them have drawbacks: some are complicated to obtain due to the high requirements the drugs need. And some even contain dangerous processes or poisonous drugs that are difficult to store. Also, there is a way that contains a lot of by-products, which makes extracting Regorafenib very difficult. In this essay, one of the synthetic routes and the data from the experiment will be used to test whether it works. Furthermore, the selected route was improved. Here, the best base on the reaction is t-BuOK; 1.1 eq of potassium tert-butoxide was preferred; the most appropriate temperature is 100°C; the ZA1 and SM3 feeding ratio is preferably 1.10 eq; the reaction time can be chosen 3-7 h.
Downloads
References
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127 (5), S5 - S16.
Bruix, J., Raoul, J. L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., ... & Llovet, J. M. (2012). Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Journal of hepatology, 57 (4), 821 - 829.
Gandomani, H. S., Aghajani, M., Mohammadian-Hafshejani, A., Tarazoj, A. A., Pouyesh, V., & Salehiniya, H. (2017). Colorectal cancer in the world: incidence, mortality and risk factors. Biomedical Research and Therapy, 4 (10), 1656 - 1675.
Haraldsdottir, S., Einarsdottir, H. M., Smaradottir, A., Gunnlaugsson, A., & Halfdanarson, T. R. (2014). Colorectal cancer-review. Laeknabladid, 100 (2), 75 - 82.
Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., & Tonini, G. (2008). The biological properties of cetuximab. Critical reviews in oncology/hematology, 68 (2), 93 - 106.
Bardelli, A., & Siena, S. (2010). Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Journal of clinical oncology, 28 (7), 1254 - 1261.
Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., ... & Laurent, D. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet, 381 (9863), 303 - 312.
Tanaka, T., Tanaka, M., Tanaka, T., & Ishigamori, R. (2010). Biomarkers for colorectal cancer. International journal of molecular sciences, 11 (9), 3209 - 3225.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







